COX-2 inhibitor arthritis testing should include low-dose aspirin users, advisory cmte. says.
This article was originally published in The Tan Sheet
Executive Summary
COX-2 Rx ARTHRITIS AGENT TESTING SHOULD INCLUDE LOW-DOSE ASPIRIN USERS as a special subpopulation, FDA's Arthritis Advisory Committee agreed at a meeting on COX-2 inhibitor safety issues held in Gaithersburg, Md. March 24. Committee member David Yocum, MD, University of Arizona, said he is "concerned about combination therapies" after hearing data that regular low-dose aspirin use leads to a higher risk of gastrointestinal complications. COX-2 inhibitors also are suspected of causing GI problems. Believed to be the next generation of arthritis drugs, COX-2 agents act as anti-inflammatories through their selective inhibition of the cyclooxygenase-2 protein. Searle, Merck and Boehringer Ingelheim are developing COX-2 products for Rx sale.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning